Screener / SEC EDGAR /CIK 0001576280 /10-K filed Feb 19, 2026, compared with Feb 20, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Medical Labs

Guardant Health, Inc. GH

Compare with peers Embed
Earnings releases

Latest results release: Nov 5, 2026

8-K item 2.02, exhibit 99

What GH's management wrote with each quarter's results: the press release and, when the company files them, its prepared remarks or the call transcript. The call itself is not filed with SEC, so most quarters have the release only.

Adjusted vs GAAP earnings per share

In the company's own words · read from each release, never computed

In its release of Nov 5, 2026, GH reported −$0.93 per share under GAAP and −$0.29 on its own adjusted basis.

GAAP EPS $-0.77, release Apr 30, 2025: Net loss per share was $0.77 for the first quarter of 2025, as compared to $0.94 for the corresponding prior year period. Adjusted EPS $-0.49, release Apr 30, 2025: Non-GAAP net loss per share was $0.49 for the first quarter of 2025, as compared to $0.46 for the corresponding prior year period. 2025-04 GAAP EPS $-0.80, release Jul 30, 2025: Net loss per share was $0.80 for the second quarter of 2025, as compared to $0.84 for the corresponding prior year period. Adjusted EPS $-0.44, release Jul 30, 2025: Non-GAAP net loss per share was $0.44 for the second quarter of 2025, as compared to $0.48 for the corresponding prior year period. 2025-07 GAAP EPS $-0.74, release Oct 29, 2025: Net loss per share was $0.74 for the third quarter of 2025, as compared to $0.88 for the corresponding prior year period. Adjusted EPS $-0.39, release Oct 29, 2025: Non-GAAP net loss per share was $0.39 for the third quarter of 2025, as compared to $0.45 for the corresponding prior year period. 2025-10 GAAP EPS $-1.00, release Feb 19, 2026: Net loss per share was $1.00 for the fourth quarter of 2025, as compared to $0.90 for the corresponding prior year period. Adjusted EPS $-0.50, release Feb 19, 2026: Non-GAAP net loss per share was $0.50 for the fourth quarter of 2025, as compared to $0.62 for the corresponding prior year period. 2026-02 GAAP EPS $-0.85, release May 7, 2026: Net loss per share was $0.85 for the first quarter of 2026, as compared to $0.77 for the corresponding prior year period. Adjusted EPS $-0.45, release May 7, 2026: Non-GAAP net loss per share was $0.45 for the first quarter of 2026, as compared to $0.49 for the corresponding prior year period. 2026-05 GAAP EPS $-0.90, release Jul 30, 2026: Net loss per share was $0.90 for the second quarter of 2026, as compared to $0.80 for the corresponding prior year period. Adjusted EPS $-0.42, release Jul 30, 2026: Non-GAAP net loss per share was $0.42 for the second quarter of 2026, as compared to $0.44 for the corresponding prior year period. 2026-07 GAAP EPS $-0.93, release Nov 5, 2026: Net loss per share was $0.93 for the third quarter of 2026, as compared to $0.74 for the corresponding prior year period. Adjusted EPS $-0.29, release Nov 5, 2026: Non-GAAP net loss per share was $0.29 for the third quarter of 2026, as compared to $0.39 for the corresponding prior year period. 2026-11
GAAP EPSAdjusted EPS, as the company defines itThe figure on top is how far adjusted is from GAAP. Click a bar for the sentence.
The company's words, latest release
Net loss per share was $0.93 for the third quarter of 2026, as compared to $0.74 for the corresponding prior year period. release
Non-GAAP net loss per share was $0.29 for the third quarter of 2026, as compared to $0.39 for the corresponding prior year period. release

What the company says its adjusted numbers leave out:

Generally Accepted Accounting Principles (GAAP) and also on a non-GAAP basis, including non-GAAP cost of precision oncology testing, non- GAAP cost of development services and other, non-GAAP cost of screening, non- GAAP gross profit, non-GAAP gross profit excluding screening, non-GAAP research and development expense, non-GAAP sales and marketing expense, non-GAAP general and administrative expense, non-GAAP other operating expense, non-GAAP loss from operations, non-GAAP net loss, non-GAAP net loss per share, basic and diluted, adjusted EBITDA, and free cash flow. release Feb 20, 2025

Both numbers are read from the words of each release (usually the highlights), never computed by us; hover a number for its sentence. Quarters where the release gives them only in a table are not shown. The company decides what "adjusted" leaves out; the full reconciliation is in the release.

Read and search

Every release, in full · linked to sec.gov

Press release Nov 5, 2026 · EX-99.1

Guardant Health Reports Third Quarter 2026 Financial Results and Increases 2026

Open on SEC

Guardant Health Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance

Third quarter 2026 revenue growth of 36% driven by strong performance in Oncology and Screening

Raises 2026 revenue guidance to $1.36 to $1.37 billion, representing growth of 38% to 40%

November 5, 2026 – Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended September 30, 2026.

For the three-month period ended September 30, 2026, as compared to the same period of 2025:

◦ Oncology revenue of $231.3 million, an increase of 25%, and 117,000 oncology tests, an increase of 58%

◦ Screening revenue of $67.6 million, an increase of 180%, and 83,000 Shield tests, an increase of 246%

• Generated non-GAAP gross margin of 67%, compared to 66% for the third quarter of 2025

• Received U.S. Food and Drug Administration (FDA) approval and CE-marking in Europe for Guardant360 CDx as a companion diagnostic for AstraZeneca’s ETCAMAH (camizestrant), the first FDA approval of a liquid biopsy companion diagnostic for longitudinal testing in breast cancer

• Received FDA approval for Guardant360 CDx as a companion diagnostic for INLURIYO (imlunestrant) in combination with VERZENIO (abemaciclib) for eligible patients with ESR1-mutated advanced or metastatic breast cancer

• Submitted a premarket approval (PMA) application to the FDA for Guardant360 Tissue • Launched Guardant Reveal Ultra with biopharma partners and remain on track for clinical launch in 2026 • Expanded commercial coverage for Shield to more than 80% of eligible lives, with key additions including UnitedHealth Group, Carelon Healthcare Services, and EviCore

• Successfully deployed the new FDA-approved lower COGS, higher-throughput Shield workflow

“Revenue grew 36% year over year as we continued to execute across Oncology, Screening, and Biopharma,” said Helmy Eltoukhy, co-founder and co-CEO. “Oncology volume grew 58% with broad contributions across our portfolio. The FDA approval of Guardant360 CDx for longitudinal ESR1 testing is a major advance for breast cancer patients, ushering in a new paradigm of cancer treatment. It reinforces the role of Guardant360 in enabling earlier therapy decisions and strengthens our leadership across the cancer care continuum.”

“Shield continued to build momentum in the third quarter, with volume more than tripling year over year to 83,000 tests,” said AmirAli Talasaz, co-founder and co-CEO. “Commercial coverage continues to expand, with recent policy updates extending Shield coverage to approximately 100 million lives. With our lower COGS, higher-throughput workflow now fully implemented, we have a strong operational foundation to meet future Shield demand. Together, these advances expand access to Shield and move us closer to making blood-based cancer screening a routine part of preventive care.” 1

Revenue was $361.0 million for the third quarter of 2026, a 36% increase from $265.2 million for the corresponding prior year period. Oncology revenue grew 25% to $231.3 million for the third quarter of 2026, from $184.4 million for the corresponding prior year period, driven primarily by an increase in Oncology test volume, which grew 58% over the prior year period. Screening revenue grew 180% to $67.6 million for the third quarter of 2026, from $24.1 million for the corresponding prior year period, driven primarily by an increase in Shield test volume, which grew to 83,000 tests in the third quarter of 2026, from 24,000 tests in the prior year period. Biopharma & Data revenue grew 8% to $59.0 million for the third quarter of 2026, from $54.7 million for the corresponding prior year period. Licensing and other revenue was $3.1 million for the third quarter of 2026, compared to $2.0 million for the corresponding prior year period.

Gross profit, or total revenue less cost of revenue, was $236.2 million for the third quarter of 2026, an increase of $64.5 million or 38%, from $171.6 million for the corresponding prior year period. Gross margin, or gross profit divided by total revenue, was 65% for the third quarter of 2026, as compared to 65% for the corresponding prior year period.

Non-GAAP gross profit was $240.2 million for the third quarter of 2026, an increase of $65.9 million or 38%, from $174.3 million for the corresponding prior year period. Non-GAAP gross margin was 67% for the third quarter of 2026, as compared to 66% for the corresponding prior year period.

Operating expenses were $368.9 million for the third quarter of 2026, as compared to $270.6 million for the corresponding prior year period. The year- over-year increase in operating expenses was primarily related to commercial infrastructure expansion and marketing activities to support Screening and Oncology growth and an increase in stock-based compensation. Non-GAAP operating expenses were $287.4 million for the third quarter of 2026, as compared to $228.9 million for the corresponding prior year period. The year-over-year increase in non-GAAP operating expenses was primarily related to commercial infrastructure expansion and marketing activities to support Screening and Oncology growth.

Net loss was $124.4 million for the third quarter of 2026, as compared to $92.7 million for the corresponding prior year period. Net loss per share was $0.93 for the third quarter of 2026, as compared to $0.74 for the corresponding prior year period.

Non-GAAP net loss was $38.8 million for the third quarter of 2026, as compared to $48.3 million for the corresponding prior year period. Non-GAAP net loss per share was $0.29 for the third quarter of 2026, as compared to $0.39 for the corresponding prior year period.

Adjusted EBITDA loss was $37.3 million for the third quarter of 2026, as compared to a $45.5 million loss for the corresponding prior year period.

Free cash flow for the third quarter of 2026 was $(37.2) million, as compared to $(45.8) million for the corresponding prior year period.

Cash, cash equivalents, and restricted cash were $1.1 billion as of September 30, 2026.

Guardant Health now expects full year 2026 revenue to be in the range of $1.36 to $1.37 billion, representing growth of 38% to 40% compared to full year 2025. This compares to the prior range of $1.34 to $1.36 billion, representing growth of 36% to 38%.

• Oncology revenue is expected to grow approximately 30% and Oncology volume is now expected to grow over 50%.

• Biopharma & Data revenue growth is expected to be in the low double-digit range.

• Screening revenue is now expected to be in the range of $233 to $238 million, driven by Shield volume of 285,000 to 290,000 tests. This compares to the prior guidance of $218 to $230 million revenue and 270,000 to 285,000 tests.

Guardant Health now expects full year 2026 non-GAAP gross margin to be 65%, compared to prior guidance of 64% to 65%. The company expects total non-GAAP operating expenses to be in the range of $1.105 to $1.125 billion, an increase compared to the prior range of $1.080 to $1.100 billion. Guardant Health now expects full-year free cash flow burn of $205 million to $220 million, compared to the previous outlook of $195 million to $205 million.

Guardant Health will host a conference call to discuss the third quarter 2026 financial results after market close on Thursday, November 5, 2026 at 1:30 pm Pacific Time / 4:30 pm Eastern Time. A webcast of the conference call can be accessed at http://investors.guardanthealth.com. The webcast will be archived and available for replay for at least 90 days after the event. 2

Guardant Health has presented in this release certain financial information in accordance with U.S. Generally Accepted Accounting Principles (GAAP) and also on a non-GAAP basis, including non-GAAP cost of revenue, non-GAAP gross profit, non-GAAP research and development expense, non-GAAP sales and marketing expense, non-GAAP general and administrative expense, non-GAAP loss from operations, non- GAAP net loss, non-GAAP net loss per share, basic and diluted, adjusted EBITDA, and free cash flow.

We define our non-GAAP measures as the applicable GAAP measure adjusted for the impacts of stock-based compensation and related employer payroll tax expense, amortization of intangible assets, impairment of non-marketable equity securities, gain on extinguishment of convertible notes, and other items, including contingent consideration and non-recurring legal expenses.

Adjusted EBITDA is defined as net loss adjusted for interest income; interest expense; other income (expense), net; provision for income taxes; depreciation and amortization expense; stock-based compensation expense and related employer payroll tax expense; and other items, including contingent consideration and non-recurring legal expenses. Free cash flow is defined as net cash used in operating activities in the period less purchases of property and equipment in the period.

We believe that the exclusion of certain income and expenses in calculating these non-GAAP financial measures can provide a useful measure for investors when comparing our period-to-period core operating results, and when comparing those same results to that published by our peers. We exclude certain items because we believe that these income and expenses do not reflect expected future operating performance. Additionally, certain items are inconsistent in amounts and frequency, making it difficult to perform a meaningful evaluation of our current or past operating performance. We use these non-GAAP financial measures to evaluate ongoing operations, for internal planning and forecasting purposes, and to manage our business.

These non-GAAP financial measures are not intended to be considered in isolation from, as substitute for, or as superior to, the corresponding financial measures prepared in accordance with GAAP. There are limitations inherent in non-GAAP financial measures because they exclude charges and credits that are required to be included in a GAAP presentation, and do not present the full measure of our recorded costs against its revenue. In addition, our definition of the non-GAAP financial measures may differ from non-GAAP measures used by other companies.

Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.

This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2025, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.

September 30, 2026 December 31, 2025 ────────────────────────────────────────────────────────────────────────────── ASSETS Current assets: Cash and cash equivalents $ 1,026,848 $ 378,203 Short-term marketable — 823,395 securities Accounts receivable, net 186,548 137,849 Inventory, net 93,490 85,876 Prepaid expenses and other current 36,519 40,723 assets Total current assets 1,343,405 1,466,046 Restricted cash 119,157 111,214 Property and equipment, net 151,474 145,915 Right-of-use assets 141,245 158,849 Intangible assets, net 24,988 25,921 Goodwill 77,257 77,257 Other assets, net 28,116 28,457 Total assets $ 1,885,642 $ 2,013,659 LIABILITIES AND STOCKHOLDERS’ DEFICIT Current liabilities: Accounts payable $ 102,512 $ 54,442 Accrued compensation 127,619 119,646 Accrued expenses 104,935 77,889 Deferred revenue 38,099 50,753 Total current liabilities 373,165 302,730 Convertible senior notes, 1,502,413 1,504,000 net Long-term operating lease 160,220 178,463 liabilities Other long-term liabilities 125,746 127,773 Total liabilities 2,161,544 2,112,966 Stockholders’ deficit: Common stock, par value of $0.00001 per share; 350,000,000 shares authorized; 134,719,874 and 130,635,301 shares 1 1 issued and outstanding as of September 30, 2026 and December 31, 2025, respectively Additional paid-in capital 3,080,321 2,900,056 Accumulated other -5,133 -4,852 comprehensive loss Accumulated deficit -3,351,091 -2,994,512 Total stockholders’ deficit -275,902 -99,307 Total liabilities and stockholders’ $ 1,885,642 $ 2,013,659 deficit

Full text with the tables
Guardant Health Reports Third Quarter 2026 Financial Results and Increases 2026 
                                Revenue Guidance                                
                                                                                
    Third quarter 2026 revenue growth of 36% driven by strong performance in    
                             Oncology and Screening                             
                                                                                
 Raises 2026 revenue guidance to $1.36 to $1.37 billion, representing growth of 
                                   38% to 40%                                   
                                                                                
  PALO ALTO, Calif.                                                             
                                                                                
November 5, 2026 – Guardant Health, Inc. (Nasdaq: GH), a leading precision
oncology company, today reported financial results for the quarter ended
September 30, 2026.
                                                                                
   Third Quarter 2026 Financial Highlights                                      
                                                                                
For the three-month period ended September 30, 2026, as compared to the same
period of 2025:

• Reported total revenue of $361.0 million, an increase of 36%, driven by:

◦ Oncology revenue of $231.3 million, an increase of 25%, and 117,000 oncology
tests, an increase of 58%

◦ Biopharma & Data revenue of $59.0 million, an increase of 8%

◦ Screening revenue of $67.6 million, an increase of 180%, and 83,000 Shield
tests, an increase of 246%

• Generated non-GAAP gross margin of 67%, compared to 66% for the third quarter
of 2025
                                                                                
  Recent Operating Highlights                                                   
                                                                                
• Received U.S. Food and Drug Administration (FDA) approval and CE-marking in
Europe for Guardant360 CDx as a companion diagnostic for AstraZeneca’s ETCAMAH
(camizestrant), the first FDA approval of a liquid biopsy companion diagnostic
for longitudinal testing in breast cancer

• Received FDA approval for Guardant360 CDx as a companion diagnostic for
INLURIYO (imlunestrant) in combination with VERZENIO (abemaciclib) for eligible
patients with ESR1-mutated advanced or metastatic breast cancer

• Submitted a premarket approval (PMA) application to the FDA for Guardant360
Tissue
• Launched Guardant Reveal Ultra with biopharma partners and remain on track for
clinical launch in 2026
• Expanded commercial coverage for Shield to more than 80% of eligible lives,
with key additions including UnitedHealth Group, Carelon Healthcare Services,
and EviCore

• Successfully deployed the new FDA-approved lower COGS, higher-throughput
Shield workflow

“Revenue grew 36% year over year as we continued to execute across Oncology,
Screening, and Biopharma,” said Helmy Eltoukhy, co-founder and co-CEO. “Oncology
volume grew 58% with broad contributions across our portfolio. The FDA approval
of Guardant360 CDx for longitudinal ESR1 testing is a major advance for breast
cancer patients, ushering in a new paradigm of cancer treatment. It reinforces
the role of Guardant360 in enabling earlier therapy decisions and strengthens
our leadership across the cancer care continuum.”

“Shield continued to build momentum in the third quarter, with volume more than
tripling year over year to 83,000 tests,” said AmirAli Talasaz, co-founder and
co-CEO. “Commercial coverage continues to expand, with recent policy updates
extending Shield coverage to approximately 100 million lives. With our lower
COGS, higher-throughput workflow now fully implemented, we have a strong
operational foundation to meet future Shield demand. Together, these advances
expand access to Shield and move us closer to making blood-based cancer
screening a routine part of preventive care.”
                                       1                                        
                                                                                
   Third Quarter 2026 Financial Results                                         
                                                                                
Revenue was $361.0 million for the third quarter of 2026, a 36% increase from
$265.2 million for the corresponding prior year period. Oncology revenue grew
25% to $231.3 million for the third quarter of 2026, from $184.4 million for the
corresponding prior year period, driven primarily by an increase in Oncology
test volume, which grew 58% over the prior year period. Screening revenue grew
180% to $67.6 million for the third quarter of 2026, from $24.1 million for the
corresponding prior year period, driven primarily by an increase in Shield test
volume, which grew to 83,000 tests in the third quarter of 2026, from 24,000
tests in the prior year period. Biopharma & Data revenue grew 8% to $59.0
million for the third quarter of 2026, from $54.7 million for the corresponding
prior year period. Licensing and other revenue was $3.1 million for the third
quarter of 2026, compared to $2.0 million for the corresponding prior year
period.

Gross profit, or total revenue less cost of revenue, was $236.2 million for the
third quarter of 2026, an increase of $64.5 million or 38%, from $171.6 million
for the corresponding prior year period. Gross margin, or gross profit divided
by total revenue, was 65% for the third quarter of 2026, as compared to 65% for
the corresponding prior year period.

Non-GAAP gross profit was $240.2 million for the third quarter of 2026, an
increase of $65.9 million or 38%, from $174.3 million for the corresponding
prior year period. Non-GAAP gross margin was 67% for the third quarter of 2026,
as compared to 66% for the corresponding prior year period.

Operating expenses were $368.9 million for the third quarter of 2026, as
compared to $270.6 million for the corresponding prior year period. The year-
over-year increase in operating expenses was primarily related to commercial
infrastructure expansion and marketing activities to support Screening and
Oncology growth and an increase in stock-based compensation. Non-GAAP operating
expenses were $287.4 million for the third quarter of 2026, as compared to
$228.9 million for the corresponding prior year period. The year-over-year
increase in non-GAAP operating expenses was primarily related to commercial
infrastructure expansion and marketing activities to support Screening and
Oncology growth.

Net loss was $124.4 million for the third quarter of 2026, as compared to $92.7
million for the corresponding prior year period. Net loss per share was $0.93
for the third quarter of 2026, as compared to $0.74 for the corresponding prior
year period.

Non-GAAP net loss was $38.8 million for the third quarter of 2026, as compared
to $48.3 million for the corresponding prior year period. Non-GAAP net loss per
share was $0.29 for the third quarter of 2026, as compared to $0.39 for the
corresponding prior year period.

Adjusted EBITDA loss was $37.3 million for the third quarter of 2026, as
compared to a $45.5 million loss for the corresponding prior year period.

Free cash flow for the third quarter of 2026 was $(37.2) million, as compared to
$(45.8) million for the corresponding prior year period.

Cash, cash equivalents, and restricted cash were $1.1 billion as of September
30, 2026.
                                                                                
  2026 Guidance                                                                 
                                                                                
Guardant Health now expects full year 2026 revenue to be in the range of $1.36
to $1.37 billion, representing growth of 38% to 40% compared to full year 2025.
This compares to the prior range of $1.34 to $1.36 billion, representing growth
of 36% to 38%.

Within this revenue range:

• Oncology revenue is expected to grow approximately 30% and Oncology volume is
now expected to grow over 50%.

• Biopharma & Data revenue growth is expected to be in the low double-digit
range.

• Screening revenue is now expected to be in the range of $233 to $238 million,
driven by Shield volume of 285,000 to 290,000 tests. This compares to the prior
guidance of $218 to $230 million revenue and 270,000 to 285,000 tests.

Guardant Health now expects full year 2026 non-GAAP gross margin to be 65%,
compared to prior guidance of 64% to 65%. The company expects total non-GAAP
operating expenses to be in the range of $1.105 to $1.125 billion, an increase
compared to the prior range of $1.080 to $1.100 billion. Guardant Health now
expects full-year free cash flow burn of $205 million to $220 million, compared
to the previous outlook of $195 million to $205 million.
                                                                                
  Webcast Information                                                           
                                                                                
Guardant Health will host a conference call to discuss the third quarter 2026
financial results after market close on Thursday, November 5, 2026 at 1:30 pm
Pacific Time / 4:30 pm Eastern Time. A webcast of the conference call can be
accessed at http://investors.guardanthealth.com. The webcast will be archived
and available for replay for at least 90 days after the event.
                                       2                                        
                                                                                
  Non-GAAP Measures                                                             
                                                                                
Guardant Health has presented in this release certain financial information in
accordance with U.S. Generally Accepted Accounting Principles (GAAP) and also on
a non-GAAP basis, including non-GAAP cost of revenue, non-GAAP gross profit,
non-GAAP research and development expense, non-GAAP sales and marketing expense,
non-GAAP general and administrative expense, non-GAAP loss from operations, non-
GAAP net loss, non-GAAP net loss per share, basic and diluted, adjusted EBITDA,
and free cash flow.

We define our non-GAAP measures as the applicable GAAP measure adjusted for the
impacts of stock-based compensation and related employer payroll tax expense,
amortization of intangible assets, impairment of non-marketable equity
securities, gain on extinguishment of convertible notes, and other items,
including contingent consideration and non-recurring legal expenses.

Adjusted EBITDA is defined as net loss adjusted for interest income; interest
expense; other income (expense), net; provision for income taxes; depreciation
and amortization expense; stock-based compensation expense and related employer
payroll tax expense; and other items, including contingent consideration and
non-recurring legal expenses. Free cash flow is defined as net cash used in
operating activities in the period less purchases of property and equipment in
the period.

We believe that the exclusion of certain income and expenses in calculating
these non-GAAP financial measures can provide a useful measure for investors
when comparing our period-to-period core operating results, and when comparing
those same results to that published by our peers. We exclude certain items
because we believe that these income and expenses do not reflect expected future
operating performance. Additionally, certain items are inconsistent in amounts
and frequency, making it difficult to perform a meaningful evaluation of our
current or past operating performance. We use these non-GAAP financial measures
to evaluate ongoing operations, for internal planning and forecasting purposes,
and to manage our business.

These non-GAAP financial measures are not intended to be considered in isolation
from, as substitute for, or as superior to, the corresponding financial measures
prepared in accordance with GAAP. There are limitations inherent in non-GAAP
financial measures because they exclude charges and credits that are required to
be included in a GAAP presentation, and do not present the full measure of our
recorded costs against its revenue. In addition, our definition of the non-GAAP
financial measures may differ from non-GAAP measures used by other companies.
                                                                                
  About Guardant Health                                                         
                                                                                
Guardant Health is a leading precision oncology company focused on guarding
wellness and giving every person more time free from cancer. Founded in 2012,
Guardant is transforming patient care and accelerating new cancer therapies by
providing critical insights into what drives disease through its advanced blood
and tissue tests, real-world data and AI analytics. Guardant tests help improve
outcomes across all stages of care, including screening to find cancer early,
monitoring for recurrence in early-stage cancer, and treatment selection for
patients with advanced cancer. For more information, visit guardanthealth.com
and follow the company on LinkedIn, X (Twitter) and Facebook.
                                                                                
  Forward Looking Statements                                                    
                                                                                
This press release contains forward-looking statements within the meaning of
federal securities laws, including statements regarding the potential utilities,
values, benefits and advantages of Guardant Health’s liquid biopsy tests or
assays, which involve risks and uncertainties that could cause the actual
results to differ materially from the anticipated results and expectations
expressed in these forward-looking statements. These statements are based on
current expectations, forecasts and assumptions, and actual outcomes and results
could differ materially from these statements due to a number of factors. These
and additional risks and uncertainties that could affect Guardant Health’s
financial and operating results and cause actual results to differ materially
from those indicated by the forward-looking statements made in this press
release include those discussed under the captions “Risk Factors” and
“Management’s Discussion and Analysis of Financial Condition and Results of
Operation” and elsewhere in its Annual Report on Form 10-K for the year ended
December 31, 2025, and in its other reports filed with or furnished to the
Securities and Exchange Commission thereafter. The forward-looking statements in
this press release are based on information available to Guardant Health as of
the date hereof, and Guardant Health disclaims any obligation to update any
forward-looking statements provided to reflect any change in its expectations or
any change in events, conditions, or circumstances on which any such statement
is based, except as required by law. These forward-looking statements should not
be relied upon as representing Guardant Health’s views as of any date subsequent
to the date of this press release.

Investor Contact:

Zarak Khurshid
[email protected]

Media Contact:
Meaghan Smith
[email protected]
                                       3                                        
                                                                                
                             Guardant Health, Inc.                              
                                                                                
                                                                                
                Condensed Consolidated Statements of Operations                 
                                                                                
                                  (unaudited)                                   
                                                                                
                     (in thousands, except per share data)                      
                                                                                
                     Three                              Nine                    
                    Months                            Months                    
                     Ended                             Ended                    
                  Septemb…                           Septem…                    
            2026       30,    2025             2026      30,    2025            
 ────────────────────────────────────────────────────────────────────────────── 
  Reven…    $      360,975    $     265,196    $     997,618    $      700,755  
  Costs                                                                         
  and                                                                           
  opera…                                                                        
  expen…                                                                        
  Cost                                                                          
  of               124,822           93,587          345,690           249,515  
  reven…                                                                        
  Resea…                                                                        
  and              100,838           89,957          288,409           265,927  
  devel…                                                                        
  expen…                                                                        
  Sales                                                                         
  and              177,218          127,375          536,304           351,279  
  marke…                                                                        
  expen…                                                                        
  Gener…                                                                        
  and               90,862           53,266          210,448           150,477  
  admin…                                                                        
  expen…                                                                        
  Total                                                                         
  costs                                                                         
  and              493,740          364,185          1,380,…          1,017,1…  
  opera…                                                                        
  expen…                                                                        
  Loss                                                                          
  from            -132,765          -98,989          -383,2…          -316,443  
  opera…                                                                        
  Inter…             9,749            7,391           31,099            24,063  
  income                                                                        
  Inter…            -1,345             -943           -4,038            -2,717  
  expen…                                                                        
  Other                                                                         
  income               342              -48              493             7,778  
  (expe…                                                                        
  net                                                                           
  Loss                                                                          
  before                                                                        
  provi…          -124,019          -92,589          -355,6…          -287,319  
  for                                                                           
  income                                                                        
  taxes                                                                         
  Provi…                                                                        
  for                  343              136              900               464  
  income                                                                        
  taxes                                                                         
  Net       $     -124,362    $     -92,725    $     -356,5…    $     -287,783  
  loss                                                                          
  Net                                                                           
  loss                                                                          
  per                                                                           
  share,    $        -0.93    $       -0.74    $       -2.68    $        -2.32  
  basic                                                                         
  and                                                                           
  dilut…                                                                        
  Weigh…                                                                        
  shares                                                                        
  used                                                                          
  in                                                                            
  compu…                                                                        
  net              134,422          124,807          132,866           124,268  
  loss                                                                          
  per                                                                           
  share,                                                                        
  basic                                                                         
  and                                                                           
  dilut…                                                                        
                                                                                
                                       4                                        
                                                                                
                             Guardant Health, Inc.                              
                                                                                
                                                                                
                     Condensed Consolidated Balance Sheets                      
                                                                                
                                  (unaudited)                                   
                                                                                
                (in thousands, except share and per share data)                 
                                                                                
                                    September 30, 2026       December 31, 2025  
 ────────────────────────────────────────────────────────────────────────────── 
  ASSETS                                                                        
  Current assets:                                                               
  Cash and cash equivalents      $           1,026,848    $            378,203  
  Short-term marketable                              —                 823,395  
  securities                                                                    
  Accounts receivable, net                     186,548                 137,849  
  Inventory, net                                93,490                  85,876  
  Prepaid expenses and other                                                    
  current                                       36,519                  40,723  
  assets                                                                        
  Total current assets                       1,343,405               1,466,046  
  Restricted cash                              119,157                 111,214  
  Property and equipment, net                  151,474                 145,915  
  Right-of-use assets                          141,245                 158,849  
  Intangible assets, net                        24,988                  25,921  
  Goodwill                                      77,257                  77,257  
  Other assets, net                             28,116                  28,457  
  Total assets                   $           1,885,642    $          2,013,659  
  LIABILITIES AND                                                               
  STOCKHOLDERS’ DEFICIT                                                         
  Current liabilities:                                                          
  Accounts payable               $             102,512    $             54,442  
  Accrued compensation                         127,619                 119,646  
  Accrued expenses                             104,935                  77,889  
  Deferred revenue                              38,099                  50,753  
  Total current liabilities                    373,165                 302,730  
  Convertible senior notes,                  1,502,413               1,504,000  
  net                                                                           
  Long-term operating lease                    160,220                 178,463  
  liabilities                                                                   
  Other long-term liabilities                  125,746                 127,773  
  Total liabilities                          2,161,544               2,112,966  
  Stockholders’ deficit:                                                        
  Common stock, par value of                                                    
  $0.00001 per                                                                  
  share; 350,000,000 shares                                                     
  authorized;                                                                   
  134,719,874 and 130,635,301                                                   
  shares                                             1                       1  
  issued and outstanding as                                                     
  of September                                                                  
  30, 2026 and December 31,                                                     
  2025,                                                                         
  respectively                                                                  
  Additional paid-in capital                 3,080,321               2,900,056  
  Accumulated other                             -5,133                  -4,852  
  comprehensive loss                                                            
  Accumulated deficit                       -3,351,091              -2,994,512  
  Total stockholders’ deficit                 -275,902                 -99,307  
  Total liabilities and                                                         
  stockholders’                  $           1,885,642    $          2,013,659  
  deficit                                                                       
                                                                                
                                       5                                        
                                                                                
                             Guardant Health, Inc.                              
                                                                                
                                                                                
                        Supplemental Revenue Information                        
                                                                                
                                  (unaudited)                                   
                                                                                
                                 (in thousands)                                 
                                                                                
                     Three                               Nine                   
                    Months                             Months                   
                     Ended                              Ended                   
                   Septem…                           Septemb…                   
             2026      30,    2025             2026       30,    2025           
 ────────────────────────────────────────────────────────────────────────────── 
  Oncolo…    $     231,264    $     184,402    $      655,323    $     493,646  
  Biopha…                                                                       
  and               58,972           54,731           172,896          156,127  
  data                                                                          
  Screen…           67,614           24,112           162,070           44,603  
  Licens…                                                                       
  and                3,125            1,951             7,329            6,379  
  other                                                                         
  Total      $     360,975    $     265,196    $      997,618    $     700,755  
  revenue                                                                       
                                                                                
         Reconciliation of Selected GAAP Measures to Non-GAAP Measures          
                                                                                
                                  (unaudited)                                   
                                                                                
                     (in thousands, except per share data)                      
                                                                                
                     Three                               Nine                   
                    Months                             Months                   
                     Ended                              Ended                   
                   Septem…                           Septemb…                   
             2026      30,    2025             2026       30,    2025           
 ────────────────────────────────────────────────────────────────────────────── 
  GAAP                                                                          
  cost of    $     124,822    $      93,587    $      345,690    $     249,515  
  revenue                                                                       
  Amorti…                                                                       
  of                  -151             -151              -449             -449  
  intang…                                                                       
  assets                                                                        
  Stock-…                                                                       
  compen…                                                                       
  expense                                                                       
  and                                                                           
  related           -3,891           -2,564           -11,047           -7,713  
  employ…                                                                       
  payroll                                                                       
  tax                                                                           
  expense                                                                       
  Non-GA…                                                                       
  cost of    $     120,780    $      90,872    $      334,194    $     241,353  
  revenue                                                                       
  GAAP                                                                          
  gross      $     236,153    $     171,609    $      651,928    $     451,240  
  profit                                                                        
  Amorti…                                                                       
  of                   151              151               449              449  
  intang…                                                                       
  assets                                                                        
  Stock-…                                                                       
  compen…                                                                       
  expense                                                                       
  and                                                                           
  related            3,891            2,564            11,047            7,713  
  employ…                                                                       
  payroll                                                                       
  tax                                                                           
  expense                                                                       
  Non-GA…                                                                       
  gross      $     240,195    $     174,324    $      663,424    $     459,402  
  profit                                                                        
  GAAP                                                                          
  resear…                                                                       
  and        $     100,838    $      89,957    $      288,409    $     265,927  
  develo…                                                                       
  expense                                                                       
  Stock-…                                                                       
  compen…                                                                       
  expense                                                                       
  and                                                                           
  related          -15,896          -13,750           -46,370          -41,095  
  employ…                                                                       
  payroll                                                                       
  tax                                                                           
  expense                                                                       
  Other                  —             -417                 —           -1,598  
  Non-GA…                                                                       
  resear…                                                                       
  and        $      84,942    $      75,790    $      242,039    $     223,234  
  develo…                                                                       
  expense                                                                       
  GAAP                                                                          
  sales                                                                         
  and        $     177,218    $     127,375    $      536,304    $     351,279  
  market…                                                                       
  expense                                                                       
  Stock-…                                                                       
  compen…                                                                       
  expense                                                                       
  and                                                                           
  related          -18,230          -11,451           -50,526          -33,396  
  employ…                                                                       
  payroll                                                                       
  tax                                                                           
  expense                                                                       
  Non-GA…                                                                       
  sales                                                                         
  and        $     158,988    $     115,924    $      485,778    $     317,883  
  market…                                                                       
  expense                                                                       
  GAAP                                                                          
  general                                                                       
  and        $      90,862    $      53,266    $      210,448    $     150,477  
  admini…                                                                       
  expense                                                                       
  Amorti…                                                                       
  of                  -128             -236              -484             -834  
  intang…                                                                       
  assets                                                                        
  Stock-…                                                                       
  compen…                                                                       
  expense                                                                       
  and                                                                           
  related          -28,291          -15,779           -72,642          -44,182  
  employ…                                                                       
  payroll                                                                       
  tax                                                                           
  expense                                                                       
  Other            -19,000             -115           -21,400           -2,835  
  Non-GA…                                                                       
  general                                                                       
  and        $      43,443    $      37,136    $      115,922    $     102,626  
  admini…                                                                       
  expense                                                                       
                                                                                
                                       6                                        
                                                                                
                     Three                               Nine                   
                    Months                             Months                   
                     Ended                              Ended                   
                   Septem…                           Septemb…                   
             2026      30,    2025             2026       30,    2025           
 ────────────────────────────────────────────────────────────────────────────── 
  GAAP                                                                          
  loss       $     -132,7…    $     -98,989    $     -383,233    $     -316,4…  
  from                                                                          
  operat…                                                                       
  Amorti…                                                                       
  of                   279              387               933            1,283  
  intang…                                                                       
  assets                                                                        
  Stock-…                                                                       
  compen…                                                                       
  expense                                                                       
  and                                                                           
  related           66,308           43,544           180,585          126,386  
  employ…                                                                       
  payroll                                                                       
  tax                                                                           
  expense                                                                       
  Other             19,000              532            21,400            4,433  
  Non-GA…                                                                       
  loss       $     -47,178    $     -54,526    $     -180,315    $     -184,3…  
  from                                                                          
  operat…                                                                       
  GAAP                                                                          
  net        $     -124,3…    $     -92,725    $     -356,579    $     -287,7…  
  loss                                                                          
  Amorti…                                                                       
  of                   279              387               933            1,283  
  intang…                                                                       
  assets                                                                        
  Stock-…                                                                       
  compen…                                                                       
  expense                                                                       
  and                                                                           
  related           66,308           43,544           180,585          126,386  
  employ…                                                                       
  payroll                                                                       
  tax                                                                           
  expense                                                                       
  Impair…                                                                       
  of                                                                            
  non-ma…                —                —                 —            5,000  
  equity                                                                        
  securi…                                                                       
  Gain on                                                                       
  exting…                                                                       
  of                     —                —                 —          -13,672  
  conver…                                                                       
  notes                                                                         
  Other             19,000              532            21,400            4,433  
  Non-GA…                                                                       
  net        $     -38,775    $     -48,262    $     -153,661    $     -164,3…  
  loss                                                                          
  GAAP                                                                          
  net                                                                           
  loss                                                                          
  per        $       -0.93    $       -0.74    $        -2.68    $       -2.32  
  share,                                                                        
  basic                                                                         
  and                                                                           
  diluted                                                                       
  Non-GA…                                                                       
  net                                                                           
  loss                                                                          
  per        $       -0.29    $       -0.39    $        -1.16    $       -1.32  
  share,                                                                        
  basic                                                                         
  and                                                                           
  diluted                                                                       
  Weight…                                                                       
  shares                                                                        
  used in                                                                       
  comput…                                                                       
  GAAP                                                                          
  and                                                                           
  Non-GA…          134,422          124,807           132,866          124,268  
  net                                                                           
  loss                                                                          
  per                                                                           
  share,                                                                        
  basic                                                                         
  and                                                                           
  diluted                                                                       
                                                                                
               Reconciliation of GAAP Net Loss to Adjusted EBITDA               
                                                                                
                                  (unaudited)                                   
                                                                                
                                 (in thousands)                                 
                                                                                
                     Three                               Nine                   
                    Months                             Months                   
                     Ended                              Ended                   
                   Septem…                           Septemb…                   
             2026      30,    2025             2026       30,    2025           
 ────────────────────────────────────────────────────────────────────────────── 
  GAAP                                                                          
  net        $     -124,3…    $     -92,725    $     -356,579    $     -287,7…  
  loss                                                                          
  Intere…           -9,749           -7,391           -31,099          -24,063  
  income                                                                        
  Intere…            1,345              943             4,038            2,717  
  expense                                                                       
  Other                                                                         
  expense             -342               48              -493           -7,778  
  (incom…                                                                       
  net                                                                           
  Provis…                                                                       
  for                  343              136               900              464  
  income                                                                        
  taxes                                                                         
  Deprec…                                                                       
  and               10,178            9,408            29,181           29,686  
  amorti…                                                                       
  Stock-…                                                                       
  compen…                                                                       
  expense                                                                       
  and                                                                           
  related           66,308           43,544           180,585          126,386  
  employ…                                                                       
  payroll                                                                       
  tax                                                                           
  expense                                                                       
  Other             19,000              532            21,400            4,433  
  Adjust…    $     -37,279    $     -45,505    $     -152,067    $     -155,9…  
  EBITDA                                                                        
                                                                                
   Reconciliation of Free Cash Flow to Net Cash Used in Operating Activities    
                                                                                
                                  (unaudited)                                   
                                                                                
                                 (in thousands)                                 
                                                                                
                     Three                               Nine                   
                    Months                             Months                   
                     Ended                              Ended                   
                   Septem…                           Septemb…                   
             2026      30,    2025             2026       30,    2025           
 ────────────────────────────────────────────────────────────────────────────── 
  Net                                                                           
  cash                                                                          
  used in    $     -23,707    $     -35,413    $     -147,108    $     -158,3…  
  operat…                                                                       
  activi…                                                                       
  Purcha…                                                                       
  of                                                                            
  proper…          -13,480          -10,350           -30,819          -20,458  
  and                                                                           
  equipm…                                                                       
  Free                                                                          
  cash       $     -37,187    $     -45,763    $     -177,927    $     -178,8…  
  flow                                                                          
                                                                                
                                       7                                        

Sources

The 8-K item 2.02 filings (SEC EDGAR) and their EX-99 exhibits: the results release and, when filed, prepared remarks or the call transcript.

Also

Said vs did: the targets in these releases against what was then reported. Filings: every filing.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/GH/export.csv") into a cell.

Next:Presentations
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.